This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Block & Leviton LLP Investigates MAP Pharmaceuticals, Inc., For Possible Breaches Of Fiduciary Duty In Connection With Its Acquisition By Allergan, Inc.

BOSTON, Jan. 23, 2013 /PRNewswire/ -- Block & Leviton LLP ( www.blockesq.com), a Boston-based law firm representing investors nationwide, has commenced an investigation into possible breaches of fiduciary duty by the Board of Directors of MAP Pharmaceuticals, Inc. ("MAP" or the "Company") (NASDAQ:  MAPP) concerning the proposed acquisition of the Company by Allergan, Inc. ("Allergan") in an all cash tender offer expected to close late in the first quarter or in the second quarter of 2013.

Under the terms of the proposed merger, Allergan will acquire MAP in a deal for approximately $25.00 per MAP share, setting a value for MAP at approximately $958 million.  The Company's stock price has been on a steady upward climb over the past two months, gaining approximately 20 percent since receiving positive drug development news in mid-November 2012.  The proposed tender offer share price fails to take into account the fact that MAP's common stock is set to soar upon the anticipated approval of its new migraine treatment LEVADEX.  Indeed, no potential acquirer would have had the highly detailed knowledge of MAP as Allergan, MAP's partner in the development of Levadex.  As such, it appears that the proposed transaction premium offers insufficient recognition of MAP's growth potential.  Analyst Carl Cachia, writing for the website Seeking Alpha, placed a price target of $30 for MAP stock by the end of 2013.

Block & Leviton's investigation seeks to determine, among other things, whether MAP's Directors breached their fiduciary duties by failing to maximize shareholder value in the proposed acquisition by Allergan and the overall fairness of the process by which the MAP Directors considered and approved the transaction.

If you are a MAP shareholder and have questions about your legal rights, or if you have information relevant to this investigation, please contact attorney Steven P. Harte, at (617) 398-5600 or email him at Steven@blockesq.com.  

Block & Leviton is a Boston-based law firm representing investors nationwide for violations of securities laws.  The firm's lawyers have collectively been prosecuting securities cases on behalf of investors for over 50 years.  This notice may constitute attorney advertising.

Contact: BLOCK & LEVITON LLP Steven P. Harte, Esq. steven@blockesq.com (617) 398-5600

SOURCE Block & Leviton LLP

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,031.14 +43.63 0.26%
S&P 500 1,984.13 -1.41 -0.07%
NASDAQ 4,518.9020 -48.6960 -1.07%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs